Fungal immunomodulatory protein (FIP) is one of the bioactive compounds of edible mushrooms, which has been shown to trigger type 1 T helper (Th1) pathway activation in research with mice. This study was designated to assess immunomodulatory effects of recombinant FIP-Flammulina velutipes (rFIP-fve) on swine and the protective efficacy against PRRSV infection. In the in vitro evaluations, rFIP-fve significantly triggered up-regulation of IL-2 and IFN-γ mRNA in porcine PBMCs and stimulated natural killer cytotoxicity. Porcine pulmonary alveolar macrophages (PAMs) treated with rFIP-fve showed prolonged life times, up-regulation of both MHC I and II molecules and enhanced abilities to present antigen. In the in vivo trial, two doses of 2 mg rFIP-fve significantly reduced drops in the CD4/CD8 ratio after PRRSV challenge, and the cytokine mRNA profile of PBMC revealed a tendency of IFN-γ up-regulation and a decrease in IL-10 in the rFIP-treated group. Moreover, administration of rFIP-fve also decreased the PRRSV viremia with 1 log10 in titer (p = 0.07) and alleviated the severity of clinical signs after PRRSV challenge. Conclusively, these results illustrate the in vitro and in vivo immunological changes of rFIP-fve administered to pigs and reveal its potential to be used as an immunomodulatory therapeutic against PRRSV infection.
Read full abstract